Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

61.59 -0.22 (-0.36%)
Streaming Delayed Price Updated: 9:37 AM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 222,458
Open 61.47
Bid (Size) 61.58 (5)
Ask (Size) 61.60 (1)
Prev. Close 61.81
Today's Range 61.36 - 61.67
52wk Range 57.16 - 74.12
Shares Outstanding 1,253,809,440
Dividend Yield 4.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
$1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.74% on an annualized basis producing an average annual return of 8.04%. Currently, Gilead Sciences has a market... 
Via Benzinga

Performance

YTD
-15.14%
-15.14%
1 Month
-5.03%
-5.03%
3 Month
+3.60%
+3.60%
6 Month
-16.04%
-16.04%
1 Year
-10.56%
-10.56%

More News

Read More
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Via Benzinga
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Recent Stock Purchase June 2022
Via Talk Markets
Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues
Via Benzinga
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
Via Investor's Business Daily
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
From Gilead Sciences, Inc.
Via Business Wire
7 Biotech Stocks With Key Catalysts Coming in July
Via InvestorPlace
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Traders See Bumpy Road Ahead For Gilead Sciences
Via Benzinga
Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
From Gilead Sciences, Inc.
Via Business Wire
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
Via Benzinga
Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions
Via Benzinga
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
Via Benzinga
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Via Benzinga
What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy
Via Benzinga
There Are Some Serious Deals In The Market Right Now
Via Talk Markets
7 Great ETFs to Buy Now for Momentum in Q2
Via InvestorPlace
Sunshine Biopharma States It Is Developing COVID Antiviral That Could Play Important Role In Treating Endemic COVID
Via Benzinga
7 Oversold Stocks to Buy Right Now
Via InvestorPlace
Gilead Joining the Global Access to Oncology Medicines Coalition
Via 3BL Media
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
From Gilead Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.